Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 5:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: FGFR2 Gene Mutation Clear all
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
Interventions
BGJ398 (infigratinib)
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
FGFR Gene Amplification, FGFR1 Gene Amplification, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR3 Gene Mutation, Head and Neck Squamous Cell Carcinoma, Human Papillomavirus Infection, Recurrent Head and Neck Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma
Interventions
BGJ398
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
Interventions
derazantinib
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Solid Tumor
Interventions
Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose range, Derazantinib at recommended phase 2 dose (RP2D)
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
8
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced May 21, 2026, 5:33 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
Interventions
Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles
Drug
Lead sponsor
Tyra Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR3 Gene Amplification, FGFR3 Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Docetaxel, FGFR Inhibitor AZD4547, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
25 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1083
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 672 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
ponatinib hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
Sameek Roychowdhury
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3, Squamous Lung Cancer With FGFR1 Amplification, Bladder Cancer With FGFR3 Mutation or Fusion, Advanced Solid Tumors With FGFR1 Amplication, Advanced Solid Tumors With FGFR2 Amplication, Advanced Solid Tumors With FGFR3 Mutation
Interventions
BGJ398
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
Interventions
BGJ398, Gemcitabine, Cisplatin
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
25
States / cities
Gilbert, Arizona • Tucson, Arizona • Little Rock, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced May 21, 2026, 5:33 PM EDT
Withdrawn Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma
Interventions
Infigratinib
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced May 21, 2026, 5:33 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, FGFR2 Gene Mutation
Interventions
Pemigatinib, Durvalumab
Drug
Lead sponsor
Mehmet Akce
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation, FGFR1 Alteration, FGFR3 Alteration
Interventions
TT-00420
Drug
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
32
States / cities
Anchorage, Alaska • Duarte, California • Santa Monica, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
FGFR2 Amplification, FGFR2 Gene Mutation, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Translocation, FGFR2 Gene Activation, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma, Other Solid Tumors, Adult
Interventions
RLY-4008
Drug
Lead sponsor
Elevar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 21, 2026, 5:33 PM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Transitional Cell Carcinoma, Platinum-Resistant Urothelial Carcinoma, Bladder Urothelial Carcinoma, FGFR Mutation, FGFR2 Gene Mutation, FGFR3 Gene Mutation, FGFR2 Amplification, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Carcinoma, Refractory Bladder Urothelial Carcinoma
Interventions
Balversa
Drug
Lead sponsor
xCures
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced May 21, 2026, 5:33 PM EDT
Not listed Phase 2 Interventional Results available
View directory record Official record
Conditions
FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR2 Gene Translocation, FGFR3 Gene Amplification, FGFR3 Gene Mutation, FGFR3 Gene Translocation, Metastatic Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Interventions
Pemigatinib, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced May 21, 2026, 5:33 PM EDT